Commonwealth of Pennsylvania Public School Empls Retrmt SYS Reduces Stake in Johnson & Johnson (JNJ)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its position in Johnson & Johnson (NYSE:JNJ) by 0.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 155,954 shares of the company’s stock after selling 301 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Johnson & Johnson were worth $17,967,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in JNJ. KAMES CAPITAL plc increased its stake in Johnson & Johnson by 1.4% in the second quarter. KAMES CAPITAL plc now owns 1,023,779 shares of the company’s stock worth $124,164,000 after buying an additional 14,212 shares during the last quarter. Kentucky Retirement Systems acquired a new stake in Johnson & Johnson during the second quarter worth approximately $28,373,000. Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in Johnson & Johnson during the second quarter worth approximately $13,472,000. Williams Jones & Associates LLC increased its stake in Johnson & Johnson by 33.5% in the second quarter. Williams Jones & Associates LLC now owns 568,774 shares of the company’s stock worth $68,992,000 after buying an additional 142,806 shares during the last quarter. Finally, Carnick & Kubik Group LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $855,000. Institutional investors and hedge funds own 65.30% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) opened at 128.07 on Tuesday. The stock has a market capitalization of $347.50 billion, a P/E ratio of 21.59 and a beta of 0.74. The company’s 50-day moving average is $119.96 and its 200-day moving average is $117.07. Johnson & Johnson has a 12 month low of $106.36 and a 12 month high of $129.00.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.56 by $0.02. The business had revenue of $18.10 billion for the quarter, compared to analysts’ expectations of $18.28 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.44 EPS. Equities analysts anticipate that Johnson & Johnson will post $7.04 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 14th. Stockholders of record on Tuesday, February 28th were issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 2.50%. The ex-dividend date was Friday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 54.42%.

Your IP Address:

Several research firms have recently weighed in on JNJ. Jefferies Group LLC reissued a “hold” rating and issued a $132.00 target price (up from $125.00) on shares of Johnson & Johnson in a research report on Saturday, March 11th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $119.73 target price on the stock. in a research report on Tuesday, March 7th. Wells Fargo & Co downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $112.28 to $112.80 in a research report on Thursday, January 26th. Royal Bank of Canada dropped their target price on shares of Johnson & Johnson from $133.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, January 25th. Finally, Goldman Sachs Group Inc dropped their target price on shares of Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 25th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $124.09.

In other news, VP Paulus Stoffels sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total transaction of $2,580,380.00. Following the transaction, the vice president now directly owns 127,650 shares in the company, valued at approximately $14,972,068.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply